Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo. Try Elite Free for 7 Days
Login Sign up free
Home Screener Maps Charts News Groups Insider Futures Forex Crypto Portfolio Calendar
Pricing
Market News Market Pulse Stocks News ETF News Crypto News

Monte Rosa Therapeutics, Inc.

Contributing Author

Recent Articles by Monte Rosa Therapeutics, Inc.

Sep-02
Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GLUE GlobeNewswire
Sep-01
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences GLUE GlobeNewswire
Aug-24
Monte Rosa Therapeutics Announces First Patient Dosed in MODeFIRe-1, a Phase 2 Study of MRT-2359 in Combination with Apalutamide in Patients with AR Mutation-Positive Metastatic Castration-Resistant Prostate Cancer GLUE GlobeNewswire
Aug-06
Monte Rosa Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates GLUE GlobeNewswire
Jul-02
Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GLUE GlobeNewswire
Jun-02
Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GLUE -9.81% GlobeNewswire
May-20
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences GLUE +6.09% GlobeNewswire
May-07
Monte Rosa Therapeutics Announces First Quarter 2026 Financial Results and Business Updates GLUE GlobeNewswire
May-05
Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GLUE GLUE +5.37% GlobeNewswire
Apr-20
Monte Rosa Therapeutics Presents Preclinical Data at American Association for Cancer Research (AACR) Annual Meeting 2026 on the Potential of its Cyclin E1 (CCNE1)-directed Molecular Glue Degrader to Treat CCNE1-amplified Solid Tumors GLUE GlobeNewswire
Mar-17
Monte Rosa Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates GLUE GlobeNewswire
Mar-16
Monte Rosa Therapeutics Announces Clinical Supply Agreement to Support Phase 2 Trial Evaluating MRT-2359 in Combination with Apalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer GLUE GlobeNewswire
Feb-24
Monte Rosa Therapeutics Presents Updated Clinical Data from Phase 1/2 Study of MRT-2359 in Combination with Enzalutamide in Heavily Pretreated Metastatic Castration-Resistant Prostate Cancer Patients at ASCO Genitourinary Cancers Symposium (ASCO GU) GLUE GlobeNewswire
Feb-23
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences GLUE GlobeNewswire
Jan-08
Monte Rosa Therapeutics Announces Pricing of $300 Million Underwritten Public Offering GLUE GlobeNewswire
Jan-07
Monte Rosa Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants GLUE +45.41% GlobeNewswire
Jan-07
Monte Rosa Therapeutics Announces Positive Interim Phase 1 Data of MRT-8102 Demonstrating Profound CRP Reductions in Elevated CVD-risk Subjects GLUE +45.41% GlobeNewswire
Jan-06
Monte Rosa Therapeutics to Present Interim MRT-8102 Phase 1 Study Results GLUE +11.18% GlobeNewswire
Dec-16
Monte Rosa Therapeutics Announces Compelling Clinical Activity of MRT-2359 in Combination with Enzalutamide in Heavily Pretreated Metastatic Castration-Resistant Prostate Cancer Patients with Androgen Receptor Mutations GLUE +13.43% GlobeNewswire
Dec-15
Monte Rosa Therapeutics to Present Updated MRT-2359 Phase 1/2 Study Results GLUE GlobeNewswire
Nov-08
Monte Rosa Therapeutics Presents Preclinical Data at AHA Scientific Sessions 2025 on the Potential of MRT-8102, a NEK7-directed Molecular Glue Degrader, to Treat Cardiovascular and Cardiometabolic Diseases GLUE GlobeNewswire
Nov-06
Monte Rosa Therapeutics Announces Third Quarter 2025 Financial Results and Business Updates GLUE +5.69% GlobeNewswire
Nov-03
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences GLUE -6.07% GlobeNewswire
Oct-24
Monte Rosa Therapeutics Presents Preclinical Data at ACR Convergence 2025 on the Potential of MRT-6160, a VAV1-directed Molecular Glue Degrader, to Treat Immune-mediated Diseases GLUE +7.32% GlobeNewswire
Sep-15
Monte Rosa Therapeutics Announces Collaboration with Novartis for Degraders to Treat Immune-mediated Diseases GLUE +44.07% GlobeNewswire
Sep-02
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences GLUE GlobeNewswire
Aug-07
Monte Rosa Therapeutics Announces Second Quarter 2025 Financial Results and Business Updates GLUE GlobeNewswire
Jul-21
Monte Rosa Therapeutics Announces First Subjects Dosed in Phase 1 Study of MRT-8102, a NEK7-Directed Molecular Glue Degrader for the Treatment of Multiple Inflammatory Diseases GLUE GlobeNewswire
Jul-03
Monte Rosa Announces Publication in Science of Key Insights that Enable Next Generation Molecular Glue Degrader Medicines GLUE GlobeNewswire
Jun-10
Monte Rosa Therapeutics Announces FDA Clearance of IND Application for MRT-8102, a NEK7-Directed Molecular Glue Degrader for the Treatment of Multiple Inflammatory Diseases GLUE GlobeNewswire
May-28
Monte Rosa Therapeutics to Participate in the Jefferies Global Healthcare Conference GLUE GlobeNewswire
May-08
Monte Rosa Therapeutics Announces First Quarter 2025 Financial Results and Business Updates GLUE +9.61% GlobeNewswire
Affiliate • Advertise • API and Exports • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information
Stock quotes delayed by 1 minute. Futures and options delayed by 15 minutes.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)